INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.62
+0.62
+3.64%
Opening 11:24 09/21 EDT
OPEN
17.00
PREV CLOSE
17.00
HIGH
18.45
LOW
16.50
VOLUME
19.26M
TURNOVER
--
52 WEEK HIGH
33.79
52 WEEK LOW
1.915
MARKET CAP
2.95B
P/E (TTM)
-10.3886
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why the Perplexing Science of Vaccines Keeps Novavax Around
From a broader perspective, Novavax (NASDAQ:NVAX) is unquestionably one of this year's biggest success stories. Just prior to 2020, NVAX stock was trading in the low single digits. Even during the depths of the Great Recession, Novavax shares managed to keep its price tag relatively respectable.
InvestorPlace · 2d ago
Why Inovio's Stock Is Trading Higher Today
Inovio Pharmaceuticals (NASDAQ: INO) shares are trading higher on Friday as traders circulate an article from Kansas City's KSHB 41 that reported the Center for Pharmaceutical Research is moving
Benzinga · 2d ago
The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals
Although companies pivoting to the development of novel coronavirus vaccines have soared this year for obvious reasons, the investment community may have been on the receiving end of a reality check. Plus, with so much profit in hand, many decided to head for the exits. However, renewed interest in the
InvestorPlace · 2d ago
INO, BKR, KODK and AHT among after-hours movers
Gainers: [[JAX]] +14%. [[KZR]] +10.3%. [[AHT]] +8%. [[KODK]] +7.9%. [[OM]] +5%.Losers: [[INO]] -3.8%. [[BTU]] -3.7%. [[EPRT]] -3.2%. [[BKR]] -3%. [[MYO]] -2.8%.
Seekingalpha · 3d ago
5 Top Stock Trades for Friday: TWLO, MU, F, INO, X
Stocks were hammered off the open and traded through a choppy Thursday following commentary from the Fed on Wednesday. With that in mind, let's look at a few top stock trades going into Friday. Top Stock Trades for Tomorrow No. 1: Twilio (TWLO) Click to EnlargeSource: Chart courtesy of StockCharts.comTwilio
InvestorPlace · 3d ago
Is AstraZeneca Still A Safe Bet?
Since the beginning of the pandemic, AstraZeneca (NYSE: AZN) was among the front-runners in the COVID-19 vaccine race. The company has joined forces with the University of Oxford to develop its candidate, AZD1222.
Benzinga · 3d ago
Inovio bear at Roth Capital unimpressed with stock's big move this week
"If the technology is so great, then at least one of those projects would have been funded to its successful completion by now," says analyst Jonathan Aschoff, affirming his Sell
Seekingalpha · 4d ago
MRSN, FSLR among premarket losers
Strongbridge Biopharma (SBBP) -16% after pricing $25M share offering.NuCana (NCNA) -16% after pricing secondary offering.Dave & Buster's Entertainment (PLAY) -13%.Xenetic Biosciences (XBIO) -9%.Mersana Therapeutics (MRSN) -8% after reporting XMT-1536 data in ovarian cancer cohort.Inovio Pharmaceuticals (INO)
Seekingalpha · 4d ago
More
No Data
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INO stock price target is 19.00 with a high estimate of 36.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 296
Institutional Holdings: 58.12M
% Owned: 34.69%
Shares Outstanding: 167.52M
TypeInstitutionsShares
Increased
73
20.21M
New
125
1.70M
Decreased
30
9.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.52%
Pharmaceuticals & Medical Research
-3.09%
Key Executives
Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Shea
Chief Operating Officer
Jacqueline Elizabeth Shea
Chief Scientific Officer
Laurent Humeau
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Jay Shepard
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average INO stock price target is 19.00 with a high estimate of 36.00 and a low estimate of 8.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.